Literature DB >> 29978915

Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.

Theresa Austria1, Christine Marion1, Vanessa Yu1, Martin Widschwendter2, David R Hinton3, Louis Dubeau1.   

Abstract

We previously described an in vitro model in which serous ovarian cystadenomas were transfected with SV40 large T antigen, resulting in loss of RB and P53 functions and thus mimicking genetic defects present in early high-grade serous extra-uterine Müllerian (traditionally called high-grade serous ovarian) carcinomas including those associated with the BRCA1 mutation carrier state. We showed that replicative aging in this cell culture model leads to a mitotic arrest at the spindle assembly checkpoint. Here we show that this arrest is due to a reduction in microtubule anchoring that coincides with decreased expression of the BUB1 kinase and of the phosphorylated form of its substrate, BUB3. The ensuing prolonged mitotic arrest leads to cohesion fatigue resulting in cell death or, in cells that recover from this arrest, in cytokinesis failure and polyploidy. Down-regulation of BRCA1 to levels similar to those present in BRCA1 mutation carriers leads to increased and uncontrolled microtubule anchoring to the kinetochore resulting in overcoming the spindle assembly checkpoint. Progression to anaphase under those conditions is associated with formation of chromatin bridges between chromosomal plates due to abnormal attachments to the kinetochore, significantly increasing the risk of cytokinesis failure. The dependence of this scenario on accelerated replicative aging can, at least in part, account for the site specificity of the cancers associated with the BRCA1 mutation carrier state, as epithelia of the mammary gland and of the reproductive tract are targets of cell-nonautonomous consequences of this carrier state on cellular proliferation associated with menstrual cycle progressions.
© 2018 UICC.

Entities:  

Keywords:  BRCA1; P53; aneuploidy; cytokinesis failure; ovarian carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29978915      PMCID: PMC6235723          DOI: 10.1002/ijc.31659

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

1.  Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression.

Authors:  Christian Boehler; Laurent R Gauthier; Oliver Mortusewicz; Denis S Biard; Jean-Michel Saliou; Anne Bresson; Sarah Sanglier-Cianferani; Susan Smith; Valérie Schreiber; François Boussin; Françoise Dantzer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-26       Impact factor: 11.205

2.  Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.

Authors:  Iris van Oostrom; Hanne Meijers-Heijboer; Litanja N Lodder; Hugo J Duivenvoorden; Arthur R van Gool; Caroline Seynaeve; Conny A van der Meer; Jan G M Klijn; Bert N van Geel; Curt W Burger; Juriy W Wladimiroff; Aad Tibben
Journal:  J Clin Oncol       Date:  2003-10-15       Impact factor: 44.544

3.  Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.

Authors:  S Zhang; I Mercado-Uribe; Z Xing; B Sun; J Kuang; J Liu
Journal:  Oncogene       Date:  2013-03-25       Impact factor: 9.867

4.  A genetically defined model for human ovarian cancer.

Authors:  Jinsong Liu; Gong Yang; Jennifer A Thompson-Lanza; Armand Glassman; Kimberly Hayes; Andrea Patterson; Rebecca T Marquez; Nelly Auersperg; Yinhua Yu; William C Hahn; Gordon B Mills; Robert C Bast
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

5.  CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation.

Authors:  Lisa Kashima; Masashi Idogawa; Hiroaki Mita; Miki Shitashige; Tesshi Yamada; Kazuhiro Ogi; Hiromu Suzuki; Minoru Toyota; Hiroyoshi Ariga; Yasushi Sasaki; Takashi Tokino
Journal:  J Biol Chem       Date:  2012-02-15       Impact factor: 5.157

Review 6.  The spindle assembly checkpoint.

Authors:  Pablo Lara-Gonzalez; Frederick G Westhorpe; Stephen S Taylor
Journal:  Curr Biol       Date:  2012-11-20       Impact factor: 10.834

7.  Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.

Authors:  Martin Widschwendter; Matthew Burnell; Lindsay Fraser; Adam N Rosenthal; Sue Philpott; Daniel Reisel; Louis Dubeau; Mark Cline; Yang Pan; Ping-Cheng Yi; D Gareth Evans; Ian J Jacobs; Usha Menon; Charles E Wood; William C Dougall
Journal:  EBioMedicine       Date:  2015-09-09       Impact factor: 8.143

8.  A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.

Authors:  Ying Liu; Hai-Yun Yen; Theresa Austria; Jonas Pettersson; Janos Peti-Peterdi; Robert Maxson; Martin Widschwendter; Louis Dubeau
Journal:  EBioMedicine       Date:  2015-09-09       Impact factor: 8.143

9.  Chromosome Bridges Maintain Kinetochore-Microtubule Attachment throughout Mitosis and Rarely Break during Anaphase.

Authors:  Judit Pampalona; Emanuele Roscioli; William T Silkworth; Brent Bowden; Anna Genescà; Laura Tusell; Daniela Cimini
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

10.  Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells.

Authors:  N Niu; I Mercado-Uribe; J Liu
Journal:  Oncogene       Date:  2017-04-24       Impact factor: 9.867

View more
  2 in total

Review 1.  Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.

Authors:  Isao Otsuka
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 2.  Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.

Authors:  Stanislas Quesada; Michel Fabbro; Jérôme Solassol
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.